Topics

Glioblastoma | Treatment | Targeted therapy | Durvalumab

Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Durvalumab

Dixit KS, Kumthekar P, Lukas RV, Williams A, Tate MC, Chandler JP, Jamshidi P, Helenowski I, Zhang H, Bloch O, Raizer JJ.
A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.
J Neurooncol. 2026 Jan 28;176(3):185. doi: 10.1007/s11060-026-05446-1. PMID: 41604000. Interventional study˰ ˍ